Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Authors
Keywords
-
Journal
BLOOD
Volume 124, Issue 4, Pages 536-545
Publisher
American Society of Hematology
Online
2014-06-10
DOI
10.1182/blood-2014-02-557819
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
- (2014) Jens G. Lohr et al. CANCER CELL
- High frequency ofIKZF1genetic alterations in adult patients with B-cell acute lymphoblastic leukemia
- (2013) Kenji Tokunaga et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The clinical significance of cereblon expression in multiple myeloma
- (2013) Steven R. Schuster et al. LEUKEMIA RESEARCH
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4
- (2012) Kwang Min Lee et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
- (2012) A. Broyl et al. BLOOD
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations
- (2012) A Dupuis et al. LEUKEMIA
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
- (2011) Shaji K. Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
- (2011) Antonia Lopez-Girona et al. BRITISH JOURNAL OF HAEMATOLOGY
- Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
- (2010) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- A human functional protein interaction network and its application to cancer data analysis
- (2010) Guanming Wu et al. GENOME BIOLOGY
- Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
- (2009) R. E. Tiedemann et al. BLOOD
- Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
- (2009) L. Escoubet-Lozach et al. CANCER RESEARCH
- Ikaros deletions are associated with poor prognosis in acute lymphoblastic leukemia
- (2009) Mhairi Copland Future Oncology
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia
- (2008) Holger Nückel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
- (2008) R A Kyle et al. LEUKEMIA
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now